An upcoming webinar from MJH Life Sciences™ will address the payer rebate deals that limit provider choice of biosimilars and complicate clinical pharmacy operations.
More biosimilars are being launched, but numerous factors affect whether they become available in the clinic. On Monday, July 20, 2020, from 5 to 6 pm EST, MJH Life Sciences™ is hosting a webinar about how biosimilar rebates shape payer policies and provider options.
The program features a panel of leading experts on oncology practice and payment who will provide perspectives on how the structuring of biosimilar payment contracts at the payer level is affecting biosimilar access and cost at the provider level.
With more biosimilars, the expectation is that costs will decline and providers will have more freedom to choose the most appropriate medications for their patients. However, marketplace dynamics have made that ideal a more complicated objective than anticipated.
Providers who want to use biosimilars find their choices of these medicines often are determined not by clinical concerns but by regional payer-by-payer contracts that necessitate careful pharmacy planning, staff training, and sometimes, compromise.
Hear what our panelists have to say about these issues and how they deal with them. They are Kathy W. Oubre, MS, chief operating officer of the Pontchartrain Cancer Center in Louisiana; Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, clinical coordinator of Hematology/Oncology for The University of Arizona Cancer Center; and Timothy Chiu, PharmD, BCPS, pharmacist evidence analyst and strategist for Kaiser Permanente.
Click here for registration information.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.